Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
Tsuzuki, Toyonori
Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism. [electronic resource] - Histopathology Mar 2014 - 484-93 p. digital
Publication Type: Journal Article
1365-2559
10.1111/his.12277 doi
Aged
Angiogenesis Inhibitors--therapeutic use
Antineoplastic Agents--therapeutic use
Carcinoma, Renal Cell--blood supply
Female
Humans
Indoles--therapeutic use
Kidney Neoplasms--blood supply
Male
Middle Aged
Neoadjuvant Therapy
Neovascularization, Pathologic--drug therapy
Nephrectomy
Niacinamide--analogs & derivatives
Phenylurea Compounds--therapeutic use
Protein Kinase Inhibitors--therapeutic use
Protein-Tyrosine Kinases--antagonists & inhibitors
Pyrroles--therapeutic use
Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors
Retrospective Studies
Sorafenib
Sunitinib
Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism. [electronic resource] - Histopathology Mar 2014 - 484-93 p. digital
Publication Type: Journal Article
1365-2559
10.1111/his.12277 doi
Aged
Angiogenesis Inhibitors--therapeutic use
Antineoplastic Agents--therapeutic use
Carcinoma, Renal Cell--blood supply
Female
Humans
Indoles--therapeutic use
Kidney Neoplasms--blood supply
Male
Middle Aged
Neoadjuvant Therapy
Neovascularization, Pathologic--drug therapy
Nephrectomy
Niacinamide--analogs & derivatives
Phenylurea Compounds--therapeutic use
Protein Kinase Inhibitors--therapeutic use
Protein-Tyrosine Kinases--antagonists & inhibitors
Pyrroles--therapeutic use
Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors
Retrospective Studies
Sorafenib
Sunitinib